Navigation Links
Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference
Date:11/26/2007

future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2006, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
2. Lexicon Pharmaceuticals to Present at the UBS Global Life Sciences Conference
3. Lexicon Appoints Judith Swain, M.D. to Board of Directors
4. Lexicon Pharmaceuticals to Present at ThinkEquity ThinkClinic
5. Lexicon Pharmaceuticals to Present at Bio InvestorForum
6. Lexicon to Report Third Quarter 2007 Financial Results on October 30, 2007
7. Lexicon Pharmaceuticals Reports 2007 Third Quarter Financial Results
8. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014 Sales Horizons, a leader ... blended sales training programs for companies engaged in complex ... used by thousands of salespeople over 25 years in ... program can be customized to address the unique sales ... blended sales training program consists of two parts: ...
(Date:7/30/2014)... July 30, 2014 BCC Research ( ... Markets for Enzymes in Industrial Applications , the global ... nearly $7.1 billion by 2018, registering a five-year compound ... estimated to be recorded in the detergent enzyme segment ... , Enzyme technology has influenced almost every sector of ...
(Date:7/30/2014)... 30, 2014  Dyadic International, Inc. ("Dyadic") (OTCQX: ... and proprietary technologies are used to discover, develop, ... the bioenergy, bio-based chemical, biopharmaceutical and industrial enzyme ... Dubinski as Vice President and Chief Financial Officer. ... and information technology operations for Dyadic and will ...
(Date:7/30/2014)... Mass. , July 30, 2014 /PRNewswire/ ... ), a biotechnology company focused on discovering, ... unmet medical needs using RNA-targeted technologies, today ... (RXI-109-1402) with RXI-109, for the reduction of ... revision surgery, has been initiated. ...
Breaking Biology Technology:Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 2Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 3Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 2Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 3Thomas Dubinski joins Dyadic as Chief Financial Officer 2Thomas Dubinski joins Dyadic as Chief Financial Officer 3Thomas Dubinski joins Dyadic as Chief Financial Officer 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 2RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 3RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 4RXi Pharmaceuticals Expands Clinical Program with Initiation of Third Phase 2a Study with RXI-109 for Treatment of Hypertrophic Scars 5
... May 1 Advanced Life Sciences,Holdings, Inc. (Nasdaq: ... the,discovery, development and commercialization of novel drugs in ... today,announced that it will host a conference call ... on Wednesday, May 7, 2008 at 10:00,a.m. (EDT). ...
... (NASDAQ: ANPI , TSX: ANP), a global ... it has received 510(k),clearance from the U.S. Food ... and 4-0 of its Quill Self-Retaining System (SRS),Polydioxanone ... a longer-lasting,absorbable suture, which is typically used for ...
... May 1 CryoLife, Inc., (NYSE: CRY ... announced today,that Harvey Morgan has been elected to ... is a Managing Director at Bentley,Associates L.P., an ... than 35 years of investment banking experience with,significant ...
Cached Biology Technology:Advanced Life Sciences to Host 2008 First Quarter Financial Results Conference Call and Webcast 2Advanced Life Sciences to Host 2008 First Quarter Financial Results Conference Call and Webcast 3Angiotech Expands Quill(TM) SRS product offering receiving FDA 510(k) approval for smaller size diameters of Quill(TM) SRS PDO 2Angiotech Expands Quill(TM) SRS product offering receiving FDA 510(k) approval for smaller size diameters of Quill(TM) SRS PDO 3Angiotech Expands Quill(TM) SRS product offering receiving FDA 510(k) approval for smaller size diameters of Quill(TM) SRS PDO 4Harvey Morgan Joins CryoLife Board of Directors 2
(Date:7/30/2014)... increase in Impact Factors for its molecular bioscience ... (Thomson Reuters, 2014) show that Clinical Science ... Biochemistry , Biochemical Society Transactions and ... their Impact Factors. The journals are owned by ... Limited. , 2014 Impact Factors (2013 Impact Factor ...
(Date:7/30/2014)... today published new research from Bjorn Brembs, professor of ... Germany, with a proof-of-concept figure allowing readers and reviewers ... This represents an important leap forward for scientific ... the quality of a scholarly output. , Figure 3 ... data and their code to F1000Research , and ...
(Date:7/30/2014)... cancer treatment has been shown to relieve patients, ... neural transmission between the peripheral and central nervous ... of Radiation Medicine, Chinese Academy of Medical Sciences, ... rat dorsal root ganglia (DRG) to provide relief ... (0, 14.8, 29.6 MBq) were implanted separately into ...
Breaking Biology News(10 mins):Across-the-board Impact Factor increases for Portland Press Limited 2F1000Research brings static research figures to life 2
... Institute for Aging Research (IFAR) at Hebrew SeniorLife, an affiliate ... specifically milk and yogurt is associated with higher bone mineral ... on the other hand, may be associated with lower BMD ... , these findings suggest that not all dairy products are ...
... reefs are predicted to decline under the pressure of ... survive at seawater temperatures even higher than predicted for ... while most species cannot, is being investigated by researchers ... York University Abu Dhabi (NYUAD). We tend ...
... February, Dennis J. Selkoe and five other "brain teasers" will ... for this honorary doctorate VIB-KU Leuven professors Bart De ... for his scientific insights, but also for his relentless search ... that cause severe damage in the brain. "The ...
Cached Biology News:New study sheds light on link between dairy intake and bone health 2How do corals survive in the hottest reefs on the planet? 2Prevention is better than cure. Also for Alzheimer's disease! 2Prevention is better than cure. Also for Alzheimer's disease! 3Prevention is better than cure. Also for Alzheimer's disease! 4
... AgarACE Enzyme(a) is a unique agarose-digesting ... quantitative recovery of intact DNA or RNA ... thermostable that low melting point (LMP) agarose ... be equilibrated to the reaction temperature before ...
... deoxynucleotidyl transferase (TdT) is an intracellular marker ... thymocytes and minor subpopulation of bone marrow ... increased numbers of TdT cells are found ... and lymphomas. Presence of TdT thus provides ...
Request Info...
... RapidStak is a fast and ... Its high capacity and reliable ... confident walk away time than typical ... of set-up make for a seamless ...
Biology Products: